Association between Statin Use and Risk of Parkinson’s Disease: Evidence from 18 Observational Studies Comprising 3.7 Million Individuals

Wu, Chieh-Chen; Islam, Md. Mohaimenul; Lee, An-Jen; Su, Chun-Hsien; Weng, Yung-Ching; Yeh, Chih-Yang; Lee, Hsun-Hua; Lin, Ming‐Chin

doi:10.3390/jpm12050825

Cited by 12 publications

(11 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 61 Up‐to‐date evidence from 15 observational studies revealed that statins use has a protective role against PD risk. 62 Following adjusting of confounding factors, the findings of this study showed that long‐duration statin use was linked with a decreased risk of PD. There was no significant decrease in the risk of PD in short‐term statin users.…”

Section: Protective Role Of Statins In Pdmentioning

confidence: 72%

See 1 more Smart Citation

Pros and cons for statins use and risk of Parkinson's disease: An updated perspective

Al-Kuraishy¹,

Al-Gareeb²,

Αλεξίου³

et al. 2023

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Parkinson's disease (PD) is the second most frequent neurodegenerative brain disease (NBD) after Alzheimer's disease (AD). Statins are the most common lipid‐lowering agents used in the management of dyslipidemia and the prevention of primary and secondary cardiovascular diseases (CVD) events. In addition, there is a controversial point regarding the role of serum lipids in the pathogenesis of PD. In this bargain, as statins reduce serum cholesterol so they affect the PD neuropathology in bidirectional ways either protective or harmful. Statins are not used in the management of PD, but they are frequently used in the cardiovascular disorders commonly associated with PD in the elderly population. Therefore, the use of statins in that population may affect PD outcomes. Concerning the potential role of statins on PD neuropathology, there are conflicts and controversies either protective against the development of PD or harmful by increasing the risk for the development of PD. Therefore, this review aimed to clarify the precise role of statins in PD regarding the pros and cons from published studies. Many studies suggest a protective role of statins against PD risk through the modulation of inflammatory and lysosomal signaling pathways. Nevertheless, other observations suggest that statin therapy may increase PD risk by diverse mechanisms including reduction of CoQ10. In conclusion, there are strong controversies regarding the protective role of statins in PD neuropathology. Therefore, retrospective and prospective studies are necessary in this regard.

show abstract

Section: Protective Role Of Statins In Pdmentioning

confidence: 72%

“…In addition, no significant difference in the reduction in the risk of PD was observed between men and women. 62 This study indicated that only long‐term statin therapy is effective against the development and progression of PD regardless of sex factor.…”

Section: Protective Role Of Statins In Pdmentioning

confidence: 76%

Pros and cons for statins use and risk of Parkinson's disease: An updated perspective

Al-Kuraishy¹,

Al-Gareeb²,

Αλεξίου³

et al. 2023

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…Furthermore, the comorbidity burden of T2DM may include other conditions that have been associated with the risk of developing PD. For instance, it has been reported that the use of statins in the context of dyslipidemia decreases the risk of PD 22 , as well as the use of beta-blockers commonly used to treat hypertension 23 . Other commonly sees metabolic disturbance seen in metabolic syndrome is in serum uric acid levels; low uric acid has been associated with morbidity, severity progression, non-motor symptoms, and motor complications of PD 24 .…”

Section: Discussionmentioning

confidence: 99%

Type 2 diabetes mellitus as a determinant factor for the age of ParkinsonÓ?s disease onset

Cervantes-Arriaga¹,

Esquivel-Zapata²,

Escobar-Valdivia³

et al. 2023

RMN

View full text Add to dashboard Cite

Objective: This study aims to identify whether type 2 diabetes mellitus (T2DM) impacts the age of Parkinson's disease (PD) onset. Methods: Consecutive people living with PD (PwP) with 2-4 years of disease duration were included and categorized according to the presence of T2DM. A 2:1 ratio randomization from the non-DM sample was performed. T2DM diagnosis was defined by a positive personal history of T2DM recorded in the medical files or reported by the subject, or the use of a hypoglycemic drug for glycemic control. A clinical assessment including the Movement Disorder Society Unified Parkinson's disease rating scale and the Hoehn and Yahr was performed by a movement disorders specialist. Results: One hundred and twenty-four non-T2DM PwP and 62 PwP with T2DM (PD-DM) were included in the study. No statistically significant differences between groups were found in motor and non-motor scores nor in disease duration. The mean age of the whole sample was 63.4 ± 11.9 years, with a mean PD duration of 3.4 ± 0.8 years. In the PD-DM group, the mean duration of T2DM was 12.4 ± 6.8 years, and T2DM was diagnosed 9.2 ± 6.8 years before the PD onset. The PD-DM group had an older age of PD onset (5.9 ± 1.6 year, p < 0.001). Conclusions: Patients with PD-DM had an older age at PD onset, suggesting a potential T2DM role in delaying the age of disease onset.

show abstract

“…A star system is used to judge the study quality with a maximum of 9 stars (4 stars for selection, 2 stars for comparability, and 3 stars for outcome). A study with 9 stars was classified as high quality, 7–8 stars as moderate, and <7 stars as low quality [ 5 , 12 , 23 ].…”

Section: Methodsmentioning

confidence: 99%

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies

Liao

Kung

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Previous epidemiological studies have raised the concern that the use of proton pump inhibitors (PPIs) is associated with an increased risk of kidney diseases. To date, no comprehensive meta-analysis has been conducted to assess the association between PPIs and the risk of chronic kidney disease (CKD). Therefore, we conducted a systematic review and meta-analysis to address the association between PPIs and CKD. The primary search was conducted in the most popular databases, such as PubMed, Scopus, and Web of Science. All observational studies evaluated the risk of CKD among PPI users, and non-users were considered for inclusion. Two reviewers conducted data extraction and assessed the risk of bias. Random-effect models were used to calculate pooled effect sizes. A total of 6,829,905 participants from 10 observational studies were included. Compared with non-PPI use, PPI use was significantly associated with an increased risk of CKD (RR 1.72, 95% CI: 1.02–2.87, p = 0.03). This updated meta-analysis showed that PPI was significantly associated with an increased risk of CKD. Association was observed in the same among moderate-quality studies. Until further randomized control trials (RCTs) and biological studies confirm these results, PPI therapy should not stop patients with gastroesophageal reflux disease (GERD). However, caution should be used when prescribing to patients with high-risk kidney disease.

show abstract

Association between Statin Use and Risk of Parkinson’s Disease: Evidence from 18 Observational Studies Comprising 3.7 Million Individuals

Cited by 12 publications

References 64 publications

Pros and cons for statins use and risk of Parkinson's disease: An updated perspective

Pros and cons for statins use and risk of Parkinson's disease: An updated perspective

Type 2 diabetes mellitus as a determinant factor for the age of ParkinsonÓ?s disease onset

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies

Contact Info

Product

Resources

About